Information Library
Results for: White Papers - Phase I/IIa
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer
June 23, 2011
In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance. -
CardioCheck
May 10, 2011
Quintiles' CardioCheck program is designed to provide rapid insight into potential cardiotoxic influences of pharmaceutical compounds. -
From Biomarkers to Diagnostics - The Road to Success
October 18, 2010
In the second installment of a two-part series, Eric Groves, Jason Hill and Christopher Ung walk through the challenges associated with drug-diagnostic co-development, addressing potential pitfalls and areas of opportunity. -
Advancing Clinical Research in Alzheimer's Disease
October 18, 2010
This report from Quintiles’ own Alzheimer’s experts gives you an inside look at the news from ICAD 2010. -
Is a REMS Request from FDA More Likely for Drugs & Biologics Indicated for Pediatric Use?
October 8, 2010
Is a REMS Request From FDA More Likely For Drugs and Biologics Indicated for Pediatric Use? -
Championing the Clinical Trial
March 31, 2009
Quintiles’ ethical standards and review procedures ensure patient safety remains the top priority for all clinical trials. The company is also leading the way for data transparency, so drug trial sponsors have instant access to information about the conduct and status of trials. -
Monitoring for Quality
May 22, 2008
Scott Cooley, Executive Director, Phase IIIb/IV Product Management, Quintiles, discusses innovative and traditional resources in a risk-based monitoring program.
Page 1 of 1 (7 results)
